## Shu G Chen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1043423/publications.pdf

Version: 2024-02-01

88 8,734 45 82
papers citations h-index g-index

92 92 92 6752 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Molecular basis of phenotypic variability in sporadc creudeldt-jakob disease. Annals of Neurology, 1996, 39, 767-778.	2.8	819
2	Truncated Forms of the Human Prion Protein in Normal Brain and in Prion Diseases. Journal of Biological Chemistry, 1995, 270, 19173-19180.	1.6	455
3	Sporadic and familial CJD: classification and characterisation. British Medical Bulletin, 2003, 66, 213-239.	2.7	449
4	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-β. Biochemistry, 2004, 43, 560-568.	1.2	362
5	LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Human Molecular Genetics, 2012, 21, 1931-1944.	1.4	356
6	Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. Scientific Reports, 2016, 6, 34477.	1.6	319
7	Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2839-2842.	3.3	308
8	Genetic influence on the structural variations of the abnormal prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10168-10172.	3.3	285
9	Typing prion isoforms. Nature, 1997, 386, 232-233.	13.7	268
10	Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature, 1997, 388, 285-288.	13.7	259
11	Chronic Wasting Disease of Elk: Transmissibility to Humans Examined by Transgenic Mouse Models. Journal of Neuroscience, 2005, 25, 7944-7949.	1.7	235
12	Aggregation and Fibrillization of the Recombinant Human Prion Protein huPrP90â^231. Biochemistry, 2000, 39, 424-431.	1.2	216
13	Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Straussler-Scheinker disease. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8322-8327.	3.3	206
14	Fatal Familial Insomnia and Familial Creutzfeldtâ€Jakob Disease: Clinical, Pathological and Molecular Features. Brain Pathology, 1995, 5, 43-51.	2.1	192
15	The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activity. Experimental Cell Research, 2007, 313, 3658-3670.	1.2	192
16	Tau gene mutation in familial progressive subcortical gliosis. Nature Medicine, 1999, 5, 454-457.	15.2	189
17	Aberrant metal binding by prion protein in human prion disease. Journal of Neurochemistry, 2001, 78, 1400-1408.	2.1	178
18	Regional distribution of protease-resistant prion protein in fatal familial insomnia. Annals of Neurology, 1995, 38, 21-29.	2.8	165

#	Article	IF	Citations
19	The Roc domain of leucineâ€rich repeat kinase 2 is sufficient for interaction with microtubules. Journal of Neuroscience Research, 2008, 86, 1711-1720.	1.3	155
20	FadA from Fusobacterium nucleatum Utilizes both Secreted and Nonsecreted Forms for Functional Oligomerization for Attachment and Invasion of Host Cells. Journal of Biological Chemistry, 2007, 282, 25000-25009.	1.6	139
21	Identification of Novel Proteinase K-resistant C-terminal Fragments of PrP in Creutzfeldt-Jakob Disease. Journal of Biological Chemistry, 2003, 278, 40429-40436.	1.6	129
22	LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiology of Disease, 2010, 40, 73-81.	2.1	128
23	Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurology, 2021, 78, 30.	4.5	125
24	Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology, 2004, 63, 436-442.	1.5	119
25	Leucineâ€rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease. Journal of Neuroscience Research, 2009, 87, 1283-1295.	1.3	109
26	Neuronal mitochondrial amelioration by feeding acetylâ€Lâ€carnitine and lipoic acid to aged rats. Journal of Cellular and Molecular Medicine, 2009, 13, 320-333.	1.6	105
27	Antibody to DNA detects scrapie but not normal prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1380-1385.	3.3	103
28	Molecular Pathology of Fatal Familial Insomnia. Brain Pathology, 1998, 8, 539-548.	2.1	98
29	Protease-Resistant Human Prion Protein and Ferritin Are Cotransported across Caco-2 Epithelial Cells: Implications for Species Barrier in Prion Uptake from the Intestine. Journal of Neuroscience, 2004, 24, 11280-11290.	1.7	96
30	Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15598-15602.	3.3	90
31	DNA Aptamers That Bind to PrP <sup>C</sup> and Not Prp <sup>Sc</sup> Show Sequence and Structure Specificity. Experimental Biology and Medicine, 2006, 231, 204-214.	1.1	89
32	Allelic origin of the abnormal prion protein isoform in familial prion diseases. Nature Medicine, 1997, 3, 1009-1015.	15.2	88
33	Prion Protein Aggregation Reverted by Low Temperature in Transfected Cells Carrying a Prion Protein Gene Mutation. Journal of Biological Chemistry, 1997, 272, 28461-28470.	1.6	86
34	Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathologica Communications, 2021, 9, 62.	2.4	79
35	Overexpression of GRK2 in alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotoxicity Research, 2006, 10, 43-56.	1.3	76
36	Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Human Molecular Genetics, 2013, 22, 328-344.	1.4	70

#	Article	IF	Citations
37	Prion protein functions as a ferrireductase partner for ZIP14 and DMT1. Free Radical Biology and Medicine, 2015, 84, 322-330.	1.3	67
38	Induction of HO-1 and NOS in Doppel-Expressing Mice Devoid of PrP: Implications for Doppel Function. Molecular and Cellular Neurosciences, 2001, 17, 768-775.	1.0	62
39	Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia. Clinics in Laboratory Medicine, 2003, 23, 43-64.	0.7	57
40	LRRK2 protein is a component of lewy bodies. Annals of Neurology, 2006, 60, 617-618.	2.8	57
41	Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. Journal of the Neurological Sciences, 2005, 229-230, 285-292.	0.3	55
42	Novel Differences between Two Human Prion Strains Revealed by Two-dimensional Gel Electrophoresis. Journal of Biological Chemistry, 2001, 276, 37284-37288.	1.6	53
43	Inhibition of brain protein kinase C subtypes by lead. Journal of Pharmacology and Experimental Therapeutics, 1993, 264, 757-61.	1.3	53
44	Insomnia associated with thalamic involvement in E200K Creutzfeldt–Jakob disease. Neurology, 2002, 58, 362-367.	1.5	50
45	Cloning of Amadoriase I Isoenzyme fromAspergillussp.: Evidence of FAD Covalently Linked to Cys342â€,‡. Biochemistry, 2000, 39, 1515-1521.	1.2	45
46	Leucine-rich repeat kinase 2: Relevance to Parkinson's disease. International Journal of Biochemistry and Cell Biology, 2006, 38, 1469-1475.	1.2	44
47	Penicillin Sulfone Inhibitors of Class D Î <sup>2</sup> -Lactamases. Antimicrobial Agents and Chemotherapy, 2010, 54, 1414-1424.	1.4	42
48	Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 2019, 29, 313-329.	5.7	42
49	Diagnostic value of skin RT-QuIC in Parkinson's disease: a two-laboratory study. Npj Parkinson's Disease, 2021, 7, 99.	2.5	41
50	LRRK2 in Parkinson's disease and dementia with Lewy bodies. Molecular Neurodegeneration, 2006, 1, 17.	4.4	40
51	Expression and Structural Characterization of the Recombinant Human Doppel Protein,. Biochemistry, 2000, 39, 13575-13583.	1.2	38
52	Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease. Human Molecular Genetics, 2015, 24, 1322-1335.	1.4	38
53	Chronic Wasting Disease of Elk and Deer and Creutzfeldt-Jakob Disease. Journal of Biological Chemistry, 2006, 281, 4199-4206.	1.6	37
54	Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease. Journal of Pathology, 2001, 194, 9-14.	2.1	36

#	Article	IF	CITATIONS
55	Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6800-6805.	3.3	35
56	Creutzfeldt-Jakob Disease (CJD) with a Mutation at Codon 148 of Prion Protein Gene. American Journal of Pathology, 2005, 167, 1729-1738.	1.9	34
57	Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Molecular Neurodegeneration, 2009, 4, 32.	4.4	34
58	Gerstmann-Strässler-Scheinker. Journal of Neuropathology and Experimental Neurology, 2006, 65, 642-651.	0.9	33
59	Leucine-Rich Repeat Kinase 2 Colocalizes with α-Synuclein in Parkinson's Disease, but Not Tau-Containing Deposits in Tauopathies. Neurodegenerative Diseases, 2008, 5, 222-224.	0.8	29
60	Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinson's Disease. Biochemistry, 2016, 55, 4519-4532.	1.2	29
61	Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 63, 157-165.	1.2	29
62	Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. Neurological Research, 2004, 26, 547-553.	0.6	28
63	Alteration of Substrate Selectivity through Mutation of Two Arginine Residues in the Binding Site of Amadoriase II from Aspergillus sp Biochemistry, 2002, 41, 4453-4458.	1.2	22
64	Assessing Prion Infectivity of Human Urine in Sporadic Creutzfeldt-Jakob Disease. Emerging Infectious Diseases, 2012, 18, 21-28.	2.0	22
65	Fusion of Doppel to Octapeptide Repeat and Nâ€Terminal Half of Hydrophobic Region of Prion Protein Confers Resistance to Serum Deprivation. Microbiology and Immunology, 2006, 50, 203-209.	0.7	20
66	Selection and characterization of DNA aptamers against PrP <sup>Sc</sup> . Experimental Biology and Medicine, 2011, 236, 466-476.	1.1	20
67	Paradoxical Role of Prion Protein Aggregates in Redox-Iron Induced Toxicity. PLoS ONE, 2010, 5, e11420.	1.1	18
68	Novel strain properties distinguishing sporadic prion diseases sharing prion protein genotype and prion type. Scientific Reports, 2017, 7, 38280.	1.6	18
69	pH-dependent kinetics of copper ions binding to amyloid- $\hat{l}^2$ peptide. Journal of Inorganic Biochemistry, 2013, 119, 21-27.	1.5	17
70	A Journey through the Species Barrier. Neuron, 2002, 34, 854-856.	3.8	16
71	Gut–microbiota–microglia–brain interactions in Alzheimer's disease: knowledge-based, multi-dimensional characterization. Alzheimer's Research and Therapy, 2021, 13, 177.	3.0	15
72	Characterization of the Prion Protein in Human Urine. Journal of Biological Chemistry, 2010, 285, 30489-30495.	1.6	14

#	Article	IF	CITATIONS
73	Sensitive Detection of Prion Protein in Human Urine. Experimental Biology and Medicine, 2005, 230, 343-349.	1.1	13
74	Divalent metal transporter, iron, and Parkinson's disease: A pathological relationship. Cell Research, 2010, 20, 397-399.	5.7	13
75	CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease. Journal of Neural Transmission, 2011, 118, 23-26.	1.4	13
76	Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls. Journal of the Neurological Sciences, 2018, 388, 203-207.	0.3	13
77	The roles of redox enzymes in Parkinson's disease: Focus on glutaredoxin. Therapeutic Targets for Neurological Diseases, 2015, 2, .	2.2	9
78	Cryptic Peptides of the Kringle Domains Preferentially Bind to Disease-Associated Prion Protein. Journal of Alzheimer's Disease, 2009, 16, 421-431.	1.2	8
79	Characterization of Prion Proteins. , 2003, 217, 305-314.		7
80	Potential longâ€term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. Alzheimer's and Dementia, 2022, 18, 1248-1259.	0.4	7
81	PrPSc typing by N-terminal sequencing and mass spectrometry. , 2000, , 209-216.		7
82	Mechanisms of phenotypic heterogeneity in prion, Alzheimer and other conformational diseases. Journal of Alzheimer's Disease, 2001, 3, 87-95.	1.2	6
83	Synergistic activation by cis-fatty acid and diacylglycerol of protein kinase C and protein phosphorylation in hippocampal slices. Neuroscience, 1995, 68, 1017-1026.	1.1	3
84	PROTEASE-RESISTANT PRION PROTEIN IN SPORADIC CREUTZFELDT-JAKOB DISEASE (CJD). Journal of Neuropathology and Experimental Neurology, 1995, 54, 416.	0.9	3
85	Molecular profiling of paired helical filaments. Journal of Alzheimer's Disease, 2001, 3, 467-469.	1.2	0
86	Advances in Prion Disease Surveillance. Advances in Clinical Chemistry, 2006, 41, 263-292.	1.8	0
87	LRRK2 Directly Interacts with DLP1 to Regulate Mitochondrial Dynamics and Function. Microscopy and Microanalysis, 2012, 18, 196-197.	0.2	0
88	Mechanisms of Phenotypic Heterogeneity in Human Prion Diseases. , 1998, , 37-41.		O